Videos
What Really Causes Multiple Myeloma? What Doctors Know So Far in 60 Seconds
Why do some people develop multiple myeloma while others don’t?
In this 60-second video, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, breaks down the top risk…
News Article
On May 20, 2025, Johnson & Johnson announced a significant milestone in the treatment of high-risk smoldering multiple myeloma (HR-SMM).
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® (…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the May 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Page
Ang International Myeloma Foundation (IMF) ay nangunguna at pandaigdigang namumuno sa larangan ng multiple myeloma. Ang aming misyon ay pahusayin ang kalidad ng buhay ng mga pasyenteng may myeloma habang nagsusumikap gumawa ng hakbang upang ito’y maiwasan at mahanapan ng lunas. Simula 1990,…
Videos
Multiple Myeloma Fatigue: A Brief Overview of Disease- and Treatment-Related Tiredness
Multiple myeloma fatigue doesn’t have to rule your life. In under 1 minute, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, shares a brief overview of fatigue…
Videos
MMR Vaccine Safety & CAR‑T Eligibility, and More: Top 10 Myeloma Patient Q&A
Multiple Myeloma Measles Risk | CAR T-cell Therapy Eligibility | Cure & Clinical Trials
Dr. Joseph Mikhael, CMO of the International Myeloma Foundation, answers the Top 10 patient…
News Article
IMF Advocates on Capitol Hill
Grassroots myeloma advocates meet with U.S. lawmakers
By Danielle Doheny, IMF Director, Public Policy & Advocacy
In March 2025, five graduates of the International Myeloma Foundation (IMF) Legislative Advocacy…
News Article
2025 Myeloma Action Month Celebrates #MyelomaMilestones
This year’s global campaign reaches more than 50 million people across 52 countries
By Peter Anton, IMF Vice President, Marketing
Myeloma Action Month (MAM) takes place every March to raise…
News Article
The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
STUDIO CITY, Calif., April 29, 2025 — Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board…
News Article
April 28, 2025—According to a press release from Regeneron Pharmaceuticals Inc., "the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The indication is specific…
Videos
Should We Screen for MGUS?
The Question the International Myeloma Foundation Aims to Answer With the iStopMM Study
Imagine stopping multiple myeloma before it ever begins. That’s the bold mission behind the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study—the largest…
Videos
Why Multiple Myeloma Is Hard to Diagnose | Signs and Symptoms Explained in a Minute
Learn why diagnosing multiple myeloma is often delayed.
IMF Chief Medical Officer Dr. Joseph Mikhael explains the vague symptoms, overlapping conditions, and testing challenges that make…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the April 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
According to a press release from GSK, Blenrep (belantamab mafodotin) has been authorized by the UK Medicine and Healthcare products Regulatory Agency (MHRA) “for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have…
Videos
CAR T-Cell Therapy Explained in Under 1 Minute | Multiple Myeloma Treatment Breakthroughs
What is CAR T-cell therapy, and how does it work to treat multiple myeloma?
In this quick, easy-to-understand video, Dr. Joseph Mikhael, Chief Medical Officer of the…
News Article
April 14, 2025—The International Myeloma Foundation (IMF) is thrilled to share that Medical Student Scholar Tyra Grischke and her mentor Dr. Ben Derman recently published their research "Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma" in Blood Cancer…
Videos
High-Risk vs. Standard-Risk Multiple Myeloma: What Patients Need to Know in 1 Minute
What’s the difference between high-risk and standard-risk multiple myeloma?
International Myeloma Foundation Chief Medical Officer Dr. Joseph Mikhael explains how risk levels are…
News Article
Over 53 Million Myeloma Milestones Shared During 2025 Myeloma Action Month
Myeloma Action Month Global Campaign Celebrates Resilience, Strengthens Connections, and Inspires Hope in 52 Countries Worldwide
STUDIO CITY, CA, April 10, 2025—At the…
News Article
According to a press release from Johnson & Johnson, "the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) formulation in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and…
Videos
Navigating Multiple Myeloma with Patient and Care Partner Team Todd and Diane Kennedy
When asked about his outlook on the future of myeloma, Todd states, “We're going to stop calling myeloma an incurable cancer. I think in 2035, we'll be doing that.” His words ignite a powerful…
Page
The International Myeloma Foundation (IMF) presents its 2025 Research Grant awards.
Videos
Myeloma Patient Questions Answered: Genetic Testing, High-Risk Myeloma, Amyloidosis & More!
Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, answers key multiple myeloma questions from patients and care partners. Learn about genetic testing,…
News Article
Featured in Blood Health, International Myeloma Foundation Chief Medical Officer Dr. Joseph Mikhael discusses recent changes to the myeloma treatment landscape. The scope of multiple myeloma treatment is evolving rapidly, bringing new hope to patients and their loved ones. In 2024…
IMF Person
Jenn Wieworka, DNP, RN, AGCNS-BC, OCN - Director, Support Groups | Mid-West
Doctorate-Prepared Nurse | Clinical Nurse Specialist | Support Group Leader
With over a decade of experience in the oncology field, Jenn is passionate about improving patient outcomes and reducing…
Videos
Watch the replay of our FBLIVE event with Dr. Urvi A. Shah, hematologist and oncologist, as she answers your crucial questions about nutrition, myeloma, and overall wellness. Learn practical tips for managing treatment side effects, dietary recommendations, and the latest research insights to…
News Article
Staying active is key for cancer survivors, and researchers at Moffitt Cancer Center are exploring whether pickleball—the nation’s fastest-growing sport—can help. Partnering with YMCA of the Suncoast, Moffitt conducted a study with 23 participants, including 18 cancer survivors, to see if playing…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the March 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Covid-19 & Myeloma in 2025: Expert Guidance from IMF Chief Medical Officer Dr. Joseph Mikhael
Are you wondering how Covid-19 continues to affect multiple myeloma patients in 2025? International Myeloma Foundation Chief Medical Officer Dr. Joseph Mikhael provides an essential…
IMF Person
Yara William, DrPH, MHA Associate Director, Support Groups | West Coast
Doctor of Public Health | Community Engager | Patient Advocate
Yara has a background in public health and health administration, with experience in nonprofit, government, and university settings. She…
IMF Person
With 20 years of nonprofit experience, Michelle is passionate about philanthropy and helping organizations grow their impact. As the Director of Prospect Development for the IMF, she brings a deep understanding of fundraising strategy, campaign planning, and making the most of data to support…
Videos
Replay the FBLIVE LIVE! Join Dr. Joe Mikhael from the International Myeloma Foundation (IMF) in this in-depth Q&A session! Directly from the IMF Patient & Family Seminar in Boca Raton, Florida, Dr. Mikhael addresses your burning questions about multiple myeloma treatment.
Learn about the…
News Article
Recognizing early signs of multiple myeloma—fatigue, bone pain, and anemia—can lead to faster diagnosis and better outcomes, says IMF Chief Medica Officer Dr. Joseph Mikhael. In this interview with CURE, Dr. Mikhael discusses how new targeted therapies, immunotherapy approaches like CAR-T…
Videos
Myeloma Patient and Advocate Todd Kennedy Answers the Internet's Top Questions About Living with Myeloma
Todd Kennedy, a myeloma patient, support group leader, and advocate, answers the most-searched questions about living with multiple myeloma.
From advice for the…
News Article
The International Myeloma Foundation Announces 2nd Annual Iceland Cycling Expedition, to be Held from August 27 – September 2
Aims to raise vital funding for the iStopMM Project and Other IMF Research Initiatives
STUDIO CITY, CA, March 13, 2025 —…
News Article
In honor of Myeloma Action Month, Amgen spoke with the International Myeloma Foundation’s (IMF) Chief Medical Officer Dr. Joseph Mikhael to uncover the latest insights on myeloma care, cutting-edge therapies, and the urgent need to address…
IMF Person
Simona Grace is the Director of Development, Major Gifts at the International Myeloma Foundation, with over a decade of experience in fundraising and development across the private, public, and nonprofit sectors. She previously led major gifts at Chrysalis, building relationships with high-net-…
Videos
Join Dr. Saad Usmani, a leading myeloma specialist from Memorial Sloan Kettering Cancer Center, for an informative Facebook Live session during Myeloma Action Month.
Dr. Saad Usmani's Myeloma Action Month Q&A offers critical insights into multiple myeloma treatment, covering advances…
Videos
Smoldering Myeloma, Bone Marrow Failure & T-Cell Therapy – Dr. Joe Answers Your Myeloma Questions
IMF Chief Medical Officer Dr. Joseph Mikhael answers your questions about myeloma, covering key topics like smoldering myeloma and bone marrow failure, CAR T-cell therapy…
Videos
Download Slides
News Article
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
STUDIO CITY, CA, March 1, 2025 — Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for…
News Article
Linvoseltamab Receives Positive CHMP Opinion for Multiple Myeloma
According to this press release from Regeneron Pharmaceuticals Inc., "the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing…
News Article
STUDIO CITY, CA, Feb 27, 2025—The International Myeloma Foundation (IMF) announced today that Mr. Yelak Biru has decided to step down as President & CEO. Mr. Biru’s last day with the organization will be on February 28, 2025.
After three years of dedicated service, Mr…
Videos
Anitocabtagene autoleucel (anito-cel), a novel anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, shows promising results in relapsed and/or refractory multiple myeloma (RRMM) patients. Initial findings from the Phase 1 and ongoing Phase 2 trials indicate high…
Videos
Elranatamab (ELRA), a bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells, showed promising results in the MagnetisMM-3 trial for relapsed or refractory multiple myeloma (RRMM). The study assessed its efficacy and safety over an extended period, including outcomes after…